
The AMR Accelerator Results
Latest news from the AMR Accelerator Projects




04/02/25 – PrIMAVeRa’s new publication on ‘Challenges in data sharing within the European community’














22/10/24 – BioVersys Joins RespiriNTM to Accelerate Development of the Broad-Spectrum Drug Candidates Against NTM Pulmonary Diseases







23/09/24 – Sustainable funding required to protect early phase antibiotics R&D for TB and beyond.

The AMR Accelerator calls to action: European capacity for antibiotic R&D requires long-term funding



13/08/24 – PrIMAVeRa project publishes on contact network dynamics to prevent pathogen transmission in hospitals












25/01/24 – Public launch of TB-Platform for the Aggregation of Preclinical Experiments Data (TB-APEX)

23/01/24 – GNA NOW consortium expands its scope to support the under-studied condition of severe diarrhoea


12/12/23 – BioVersys receives U.S. FDA orphan-drug designation for alpibectir and ethionamide fixed-dose combination for treatment of tuberculosis


24/11/23 – PrIMAVeRa provides in-depth reports on current evidence base of burden of AMR in Europe

24/11/23 – PrIMAVeRa 2nd annual meeting successfully held in hybrid format in Utrecht on 15-16 November 2023



08/11/23 – A new dawn in the fight against Tuberculosis: UNITE4TB announces start of clinical trials









16/02/23 – ERA4TB to partner with UNITE4TB for webinar focusing on community engagement in TB research







12/12/22 – The power of words: the importance of appropriate language use in TB communications from UNITE4TB



16/11/22 – Meaningful engagement of the community in TB Research & Development: Best practice initiative from UNITE4TB

25/10/22 – New publication from GNA NOW Consortium published by the American Society for Microbiology

17/10/22 – ERA4TB Webinar on Challenges of tuberculosis (TB) drug development and access – clinical, regulatory and HTA perspectives







08/06/22 – Positive results for preclinical development of the first-in-class antibiotics NOSO-502











18/11/21 – Tuberculosis projects represent the biggest ever funding effort to combat the disease















Learn more about the AMR Accelerator Projects
Link to: AB-Direct
- 7 participants
- > 3.7 M€ budget
- 4 years & 3 months. Started 1 July 2019
Antibiotic distribution and recovery in tissue

Link to: COMBINE
- 11 participants
- 25 M€ budget
- 6 years. Started 1 Nov 2019
Coordination and support across the AMR Accelerator. Research to strengthen the scientific basis in the AMR field.

Link to: ERA4TB
- 32 participants
- > 207 M€ budget
- 6 years. Started 1 Jan 2020
Development of anti-TB drug combinations

Link to: GNA NOW
- 12 participants
- 21.6 M€ budget
- 6 years. Started 1 July 2019
New antibiotics to treat Gram-negative infections

Link to: PrIMAVeRa
- 18 participants
- 9.25 M€ budget
- 5 years. Started 1 November 2021
Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance

Link to: RespiriNTM
- 9 participants
- > 8 M€ budget
- 6 years. Started 1 May 2019
Novel assets for non-tuberculous mycobacteria

Link to: RespiriTB
- 9 participants
- > 9.9 M€ budget
- 6 years. Started 1 May 2019
New assets for multidrug-resistant tuberculosis

Link to: TRIC-TB
- 2 participants
- > 8.3 M€ budget
- 4 years & 10 months. Started 1 May 2019
Defining a new place for Ethionamide in 1st-line TB treatments




Follow us:
The AMR Accelerator has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreements No 853967 I 853989 I 853979 I 853932 I 853800 I 853903 I 853976 I 101007873 I 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. ERA4TB receives additional support from Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee. UNITE4TB receives additional support from Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. https://www.imi.europa.eu/ |